Wyeth Zosyn dosing revision
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryWyeth's Zosyn (piperacillin/tazobactam) clears FDA April 28 for treatment of nosocomial pneumonia in a four-times-daily dosing regimen. The injectable antibiotic/beta lactamase inhibitor combination was previously approved for dosing six times per day. Wyeth had manufacturing difficulties with Zosyn in 2002, but the firm reported April 23 that manufacturing is back to full capacity. First quarter 2003 sales were $140 mil., up 37
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.